Daniel Ek's Neko Health raises €612.7 million Series C as it prepares for US expansion
Swedish health tech company Neko Health has completed a €612.7 million Series C funding round to expand into the United States and further develop its preventive healthcare offerings.
Neko Health, the Stockholm-based health tech company, has announced the completion of its €612.7 million ($700 million) Series C funding round, with the company preparing to launch its first US clinics in New York and other cities this year.
The round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with participation from existing investors Atomico, General Catalyst, and Lakestar, alongside new backers including Liberty City Ventures, Positive Sum, and BDT & MSD. As part of the round, David Ofer of O.G. Venture Partners will join the Board of Directors. This fundraise follows a €250 million Series B in January 2025.
The funding round also saw participation from notable names such as Maria Sharapova, Mark Zuckerberg and Priscilla Chan, Thierry Henry, Ari Emanuel, Claudia Schiffer and Sir Matthew Vaughn, Danny Meyer, Jimmy Iovine, Tim Ferriss, and will.i.am. They joined existing investors including Alexis Ohanian from Seven Seven Six, Alex Tew and Michael Acton-Smith from Calm, Gary Vaynerchuk, Jessie Inchauspé, Katie Haun, Raj Shamani, Steven Bartlett, Zoë Saldaña, and Marco Perego-Saldaña.
Hjalmar Nilsonne, co-founder and CEO of Neko Health, said the funding is a strong vote of confidence in the company's mission to create a completely new healthcare experience focused on prevention, early detection, and disease avoidance. He noted that the vast majority of members return after their first scan, and their health markers improve.
Founded in 2023 by Nilsonne and Daniel Ek (CEO and co-founder of Spotify), Neko Health aims to provide proactive rather than reactive healthcare. Its model combines proprietary in-house technology, clinical research, and in-person clinician analysis.
The core product is the Neko Health Scan, a 60-minute, non-invasive, radiation-free health assessment that captures millions of health data points. Priced at £299 in the UK and 2,750 SEK in Sweden, the scan uses proprietary sensors and blood analysis to assess skin health, biomarkers for pre-diabetes, blood abnormalities, and risk factors for metabolic syndrome, stroke, and heart attack. Results are delivered on-site within minutes and discussed during an in-person consultation.
This funding news comes three weeks after the company's most significant scan advancement to date. The scan now captures body composition measures in seconds, and clinician review of wearable data is live across all clinics. Neko builds all its hardware, software, and consumer experience in-house.
Last month, Neko opened a new clinic in Stockholm centered on next-generation medical devices: Derma-2, Echo-2, and Spectrum-2. These devices capture higher-fidelity health signals for skin, heart, and circulation with increased automation. They will be rolled out to all clinics in the coming months.
Since launching in February 2023, Neko Health has expanded in Sweden and the UK, including Manchester, Birmingham, and multiple London locations. Over 350,000 people have registered for a scan, and more than 100,000 have experienced one. On average, 75% of members book and prepay for a scan the following year at the end of their appointment. The company's data shows that early detection leads to health improvements: three in four returning members with previously identified severe conditions are in good health or have their condition under control. Five of seven key biomarkers showed statistically significant improvement between Scan 1 and Scan 2.
